Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Opening Session Panel Discussion

Advertisement

Advertisement




Oct
05
Today In Oncology
ER-Positive HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
FDA Approves First-Line Pirtobrutinib for CLL-SLL
Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo